Lysostaphin is an antistaphylococcal agent. Lysostaphin has activities of three enzymes namely, glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase^[1].

Lysostaphin (16 μg/mL, 0-260 minutes) exerts its antibacterial effect by hydrolyzing the peptidoglycan cross-linkages of Staphylococcus aureus, weakening the mechanical strength of the cell wall and causing structural damage^[3].
Product Information
Molecular weight: 27 kDa
Effective pH range: 5.0-8.0

Instructions
Can be dissolved in ddH₂O at a concentration of 1 mg/mL. Fresh preparation is recommended. Or dissolve in buffer according to specific experimental references.

Notes
PCMB, PMSF, DTT, etc. have no obvious effect on enzyme activity at 1 mM. Ba²⁺, Mn²⁺, Ca²⁺, Mg²⁺ and EDTA show a certain degree of inhibitory effect on enzyme activity at a concentration of 1 mM.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lysostaphin (5 mg/kg, intravenous injection, once daily for 3 consecutive days) effectively clears systemic Staphylococcus aureus (MSSA) infections in CF-1 mice^[2].
Lysostaphin (50 mg/kg, intravenous injection, single dose) effectively clears Staphylococcus aureus (MSSA and MRSA) infections from the kidneys, spleen, and liver, but is not superior to repeated lower doses^[2].
Lysostaphin (1 mg/kg, intravenous injection, once daily for 3 consecutive days) combined with Oxacillin (HY-B0925A) achieves the same antibacterial effect with a lower concentration of Lysostaphin. When combined with Vancomycin, low-dose Lysostaphin (1 mg/kg) similarly shows enhanced efficacy against MRSA^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

9011-93-2

Solid

White to off-white

[Lysostaphin]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jaspal K Kumar, et al. Lysostaphin: An Antistaphylococcal Agent. Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61.  [Content Brief]

  [2]. Kokai-Kun JF, et al. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother. 2007 Nov;60(5):1051-9.  [Content Brief]

  [3]. Francius G, et al. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin. J Bacteriol. 2008 Dec;190(24):7904-9.  [Content Brief]